Dexcom director plans sale of 6,539 shares

DEXCOM INC (DXCM) received a Rule 144 notice for a proposed sale of up to 6,539 shares of common stock by director Nicholas Augustinos through Fidelity Brokerage Services LLC.

Rhea-AI Filing Summary

DEXCOM INC (DXCM) received a Rule 144 notice for a proposed sale of up to 6,539 shares of common stock by director Nicholas Augustinos through Fidelity Brokerage Services LLC. The shares derive from vested RSU grants dated May 8, 2026 and May 19, 2022.

The proposed sale represents an aggregate market value of $549,537.56, with 377,360,765 shares of Dexcom common stock outstanding as of September 15, 2026. In the prior three months, Augustinos sold 1,550 shares for $130,231.00 under Rule 144.

Key Figures

Shares to be sold under Rule 144: 6,539 shares Aggregate market value of shares: $549,537.56 Dexcom shares outstanding: 377,360,765 shares +4 more

7 metrics

Shares to be sold under Rule 144 6,539 shares Proposed Dexcom common stock sale by director Nicholas Augustinos

Aggregate market value of shares $549,537.56 Market value of 6,539 Dexcom common shares covered by the notice

Dexcom shares outstanding 377,360,765 shares Common stock outstanding as of September 15, 2026

Shares from May 8, 2026 vested RSU grant 3,496 shares Dexcom common stock from a vested RSU grant dated May 8, 2026

Shares from May 19, 2022 vested RSU grant 3,043 shares Dexcom common stock from a vested RSU grant dated May 19, 2022

Recent 3‑month sale volume 1,550 shares Shares of Dexcom common stock sold on September 14, 2026

Proceeds from recent sale $130,231.00 Value of 1,550 Dexcom shares sold on September 14, 2026

Key Terms

Rule 144, vested RSU grant, common stock

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

vested RSU grant financial

"Common Stock | 05/08/2026 | Vested RSU Grant | DEXCOM, INC."

common stock financial

"Common Stock | Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Dexcom (DXCM)?

It reports that director Nicholas Augustinos has given notice under Rule 144 of a proposed sale of up to 6,539 Dexcom common shares. This is a disclosure of a potential insider sale, not an action by Dexcom itself.

How many Dexcom (DXCM) shares is Nicholas Augustinos planning to sell?

The notice covers a proposed sale of up to 6,539 shares of Dexcom common stock. These shares are associated with vested RSU grants dated May 8, 2026 (3,496 shares) and May 19, 2022 (3,043 shares).

What is the market value of the Dexcom (DXCM) shares in the Rule 144 notice?

The 6,539 Dexcom common shares in the Rule 144 notice have an aggregate market value of $549,537.56, based on the price information used in the notice for the proposed transactions on NASDAQ.

How many Dexcom (DXCM) shares were outstanding at the time of the notice?

Dexcom had 377,360,765 shares of common stock outstanding as of September 15, 2026, according to the information provided in the notice related to the Rule 144 sale.

What Dexcom (DXCM) share sales has Nicholas Augustinos made recently?

In the three months before the notice, Nicholas Augustinos sold 1,550 Dexcom common shares on September 14, 2026 for total proceeds of $130,231.00, as reported in the recent-activity section.

Through which broker will the Dexcom (DXCM) Rule 144 shares be sold?

The proposed sale of Dexcom common stock is to be executed through Fidelity Brokerage Services LLC, located at 245 Summer Street, Boston, MA 02110, as identified in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 09:53 AM Accepted by SEC EDGAR 09/15/2026 - 09:52 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001238485
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM INC
SEC File Number	000-51222
Address of Issuer	6340 SEQUENCE DRIVE SAN DIEGO CALIFORNIA 92121
Phone	8582000200
Name of Person for Whose Account the Securities are To Be Sold	AUGUSTINOS NICHOLAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	6539	549537.56	377360765	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/08/2026	Vested RSU Grant	DEXCOM, INC.			3496	05/08/2026	N/A
Common Stock	05/19/2022	Vested RSU Grant	DEXCOM, INC.			3043	05/19/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
NICHOLAS AUGUSTINOS C/O DEXCOM INC 6340 SEQUENCE DRIVE San Diego CA 92121	Common Stock	09/14/2026	1550	130231.00

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey Skillern, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Nicholas Augustinos
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)